Monoclonal antibodies (mAbs) are large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances. Monoclonal antibodies are finding wide application in many areas of medicine and biologic science. These antibodies have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory. Monoclonal antibodies have also been extensively used in radioimmunoassay to measure serum levels of various substances. They have very useful in quantitating types of WBCs and subgroups of lymphocytes. They are also used in the diagnosis of leukemia. More recently, monoclonal antibodies have been used in the treatment of malignancies. They have been used to treat transplant rejection episodes, purge bone marrow of tumor cells in bone marrow transplants, and remove mature T cells that cause GVH disease in bone marrow transplants.
There are several types of monoclonal antibodies on the market and in development. Most of the monoclonal antibodies on the market are whole antibodies, while some are fragments of antibodies. There are also variable fragment monoclonal antibodies and bispecific monoclonal antibodies.
There are several types of monoclonal antibodies on the market and in development. Most of the monoclonal antibodies on the market are whole antibodies, while some are fragments of antibodies. There are also variable fragment monoclonal antibodies and bispecific monoclonal antibodies.
All reports in Antibody Technologies
|
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides
5/1/2012 | published by: BioSeeker Group AB
... to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...
|
more...
|
$5,175.00
|
|
Global Protein Therapeutics Market Forecast to 2015
4/1/2012 | published by: RNCOS
... from cancer to metabolic disorders. Despite the post-recessionary impact worldwide causing major slump in the healthcare spending, the protein therapeutics market continued to grow at its retained speed. According to our report, the market still ...
|
more...
|
$2,000.00
|
|
Strategic Analysis of the U.S. Research Antibodies Market
3/30/2012 | published by: Frost & Sullivan
... detection and quantification of particular targets within a sample. Provided within the study is a detailed history and market overview, important market metrics, key market drivers and restraints, and an analysis on competitive dynamics and ...
|
more...
|
$6,000.00
|
|
Research Report on Chinese Monoclonal Antibody Industry, 2012
3/7/2012 | published by: China Research and Intelligence Co., Ltd.
... and immune system diseases and has good application prospects in clinical treatment. From the point of the global market, antibody medicine accounts for over 40% of the entire biotechnology medicine. With constant growth of the ...
|
more...
|
$3,000.00
|
|
Conference Documentation: Superbugs & Superdrugs - A Focus on Antibacterials
3/6/2012 | published by: SMI Publishing, Ltd
... stories and failures enabling attendees to learn from and discuss with key industry professionals on challenges facing this rapidly-evolving field. Senior industry executives in the field will present on their experiences of antibiotic resistance and ...
|
more...
|
$800.00
|
|
Hematological Cancer Therapies
3/1/2012 | published by: CHI Insight Pharma Reports
... well as challenges and opportunities for pharmaceutical companies. This report discusses: The different types of hematological cancers, including information about the specific disease, its epidemiology, subtypes and/or staging if appropriate, current therapies, and patient prognosis. ...
|
more...
|
$2,495.00
|
|
Cancer Monoclonal Antibodies Market to 2015
3/1/2012 | published by: RNCOS
... years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal ...
|
more...
|
$1,500.00
|
|
Laboratory Chemical Reagents
3/1/2012 | published by: Global Industry Analysts
... Reagents, Enzymes, & Others), Biochemistry (IVD), Cytokine & Chemokine Testing, Cell/Tissue Culture, Carbohydrate Analysis, Immunohistochemistry, and Environmental Testing (Pesticide Residues, & Others). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, ...
|
more...
|
$4,950.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Antibodies
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Antibodies
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Pancreatic Cancer and Antibodies
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies
3/1/2012 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Pancreatic Cancer, Antibodies and Peptides
3/1/2012 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Pancreatic Cancer, Apoptosis and Antibodies
3/1/2012 | published by: BioSeeker Group AB
... to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area ...
|
more...
|
$5,175.00
|


